Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia. Issue 10 (11th June 2014)

• Record Type: Journal Article
• Authors: Zhang, Li; Cao, Zeng; Ruan, Min; Zeng, Qiang; Zhao, Liang; Li, Qinghua; Zou, Yao; Wang, Jianxiang; Zhu, Xiaofan
• Is Part Of: Pediatric blood & cancer. Volume 61:Issue 10(2014:Oct.)
• Page Start: 1761
• Page End: 1766
• Publication Date: 2014-06-11
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.25109
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="pbc25109-sec-0001" sec-type="section"> <title>Background</title> <p>To determine the prognostic significance of the detection of the minimal residual disease (MRD) in children with AML1/ETO AML, we compared the results of reverse‐transcription polymerase chain reaction (RT‐PCR) and quantitative reverse‐transcription polymerase chain reaction (RQ‐PCR).</p> </sec> <sec id="pbc25109-sec-0002" sec-type="section"> <title>Procedure</title> <p>Between January 2006 and February 2013, 70 patients (≤16 years of age) with AML1/ETO AML were included in our study. Bone marrow samples were evaluated using by both RT‐PCR and RQ‐PCR assays. AML1/ETO transcripts were normalized to 10<sup>5</sup> ABL copies.</p> </sec> <sec id="pbc25109-sec-0003" sec-type="section"> <title>Results</title> <p>When treated with fewer than four courses of therapy, no association was found between positive RT‐PCR results and relapse. After four courses of therapy, a positive RT‐PCR result was correlated with a probability of relapse. After induction chemotherapy, a >1.8 log reduction in AML1/ETO transcripts in BM determined by RQ‐PCR may represent a subgroup of patients at low risk for relapse. MRD levels after consolidation (Courses 2 and 3) were also informative.</p> </sec> <sec id="pbc25109-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Both RT‐PCR and RQ‐PCR can be used to detect MRD in childhood AML1/ETO AML. RQ‐PCR can identify patients who are at high risk of relapse earlier than can RT‐PCR. Pediatr Blood Cancer 2014; 61:1761–1766. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>